Chronic Hand Eczema
Conditions
Brief summary
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.
Interventions
DRUGDelgocitinib
Cream for topical application 20 mg/g
DRUGToctino
1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
Sponsors
LEO Pharma
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main inclusion criteria: * Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months. * Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4). * Participants who have a documented recent history of inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks). * Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens. * Participants must use contraceptive methods in accordance with local regulations regarding the methods of contraception for those participating in clinical studies Main
Exclusion criteria
* Concurrent skin diseases on the hands, e.g. tinea manuum. * Active atopic dermatitis requiring medical treatment in regions other than the hands and feet. * Active psoriasis on any part of the body. * Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body. * Clinically significant infection on the hands. * Participants who cannot receive alitretinoin. * Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial. * History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report. * Any disorder which is not stable and could: * Affect the safety of the participant throughout the trial. * Impede the participant's ability to complete the trial. * Positive hepatitis B surface antigen or hepatitis C virus antibody serology at screening. * Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline. * Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline. * Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical. * Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline. * Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline. * Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline. * Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline. * Treatment with any marketed biological therapy or investigational biologic agents: * Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer. * Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline. * Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HECSI Score From Baseline to Week 12 | 12 weeks | The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IGA-CHE TS at Week 12. | 12 weeks | The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline. |
| Change in HESD Itch Score (Weekly Average) From Baseline to Week 12 | 12 weeks | The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component. |
| Change in HESD Pain Score (Weekly Average) From Baseline to Week 12. | 12 weeks | The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component. |
| AUC of HECSI-90 From Baseline up to Week 24 | 24 weeks | The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24. |
| HECSI-90 at Week 12 | 12 weeks | The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. |
| Change in HECSI Score From Baseline to Week 24 | 24 weeks | The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. |
| Number of Treatment-emergent AEs From Baseline up to Week 26 | 26 weeks | An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP. |
| Number of Treatment-emergent SAEs From Baseline up to Week 26 | 26 weeks | A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP. |
| Number of AEs Leading to IMP Discontinuation up to Week 24 | 24 weeks | The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE). |
| AUC of Change From Baseline in DLQI Score up to Week 24 | 24 weeks | The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening. |
Countries
Austria, Canada, France, Germany, Italy, Norway, Poland, Slovakia, Spain, United Kingdom
Participant flow
Recruitment details
The trial enrolled adult participants with severe CHE and with a documented inadequate response to treatment with TCS or for whom TCS were documented to be otherwise medically inadvisable.
Pre-assignment details
Randomization was stratified by subtype (hyperkeratotic/non-hyperkeratotic) and region (North America/Europe).
Participants by arm
| Arm | Count |
|---|---|
| Delgocitinib Cream 20 mg/g Twice-daily topical application for up to 24 weeks\>
\> Delgocitinib: Cream for topical application 20 mg/g | 254 |
| Alitretinoin Capsules 30 mg Per Capsule 1 capsule per day for up to 24 weeks\>
\> Toctino: 1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur | 259 |
| Total | 513 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 24 |
| Overall Study | Discontinuation of IMP, related to COVID-19 | 1 | 0 |
| Overall Study | Lack of Efficacy | 8 | 26 |
| Overall Study | Lost to Follow-up | 5 | 1 |
| Overall Study | Not exposed to IMP | 1 | 12 |
| Overall Study | Various reasons | 3 | 9 |
| Overall Study | Withdrawal by Subject | 15 | 33 |
Baseline characteristics
| Characteristic | Delgocitinib Cream 20 mg/g | Alitretinoin Capsules 30 mg Per Capsule | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 16 Participants | 26 Participants | 42 Participants |
| Age, Categorical Between 18 and 65 years | 238 Participants | 233 Participants | 471 Participants |
| Age, Continuous | 45.4 years STANDARD_DEVIATION 13.78 | 44.0 years STANDARD_DEVIATION 14.56 | 44.7 years STANDARD_DEVIATION 14.18 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 22 Participants | 14 Participants | 36 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 226 Participants | 241 Participants | 467 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 6 Participants | 4 Participants | 10 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) Asian | 9 Participants | 5 Participants | 14 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 3 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 6 Participants | 7 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants | 2 Participants | 5 Participants |
| Race (NIH/OMB) White | 237 Participants | 240 Participants | 477 Participants |
| Region of Enrollment Austria | 2 participants | 3 participants | 5 participants |
| Region of Enrollment Canada | 25 participants | 29 participants | 54 participants |
| Region of Enrollment France | 14 participants | 16 participants | 30 participants |
| Region of Enrollment Germany | 63 participants | 73 participants | 136 participants |
| Region of Enrollment Italy | 13 participants | 9 participants | 22 participants |
| Region of Enrollment Norway | 1 participants | 1 participants | 2 participants |
| Region of Enrollment Poland | 89 participants | 91 participants | 180 participants |
| Region of Enrollment Slovakia | 9 participants | 5 participants | 14 participants |
| Region of Enrollment Spain | 36 participants | 28 participants | 64 participants |
| Region of Enrollment United Kingdom | 2 participants | 4 participants | 6 participants |
| Sex: Female, Male Female | 167 Participants | 167 Participants | 334 Participants |
| Sex: Female, Male Male | 87 Participants | 92 Participants | 179 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 253 | 0 / 247 |
| other Total, other adverse events | 58 / 253 | 143 / 247 |
| serious Total, serious adverse events | 5 / 253 | 12 / 247 |
Outcome results
Primary
Change in HECSI Score From Baseline to Week 12
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | Change in HECSI Score From Baseline to Week 12 | -67.6 score on a scale | Standard Error 3.37 |
| Alitretinoin Capsules 30 mg Per Capsule | Change in HECSI Score From Baseline to Week 12 | -51.5 score on a scale | Standard Error 3.36 |
Comparison: The change from baseline was analysed using an ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed with WOCF. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: <0.00195% CI: [-23.28, -8.86]ANCOVA
Secondary
AUC of Change From Baseline in DLQI Score up to Week 24
The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | AUC of Change From Baseline in DLQI Score up to Week 24 | 1124.7 days * DLQI score reduction | Standard Error 61.37 |
| Alitretinoin Capsules 30 mg Per Capsule | AUC of Change From Baseline in DLQI Score up to Week 24 | 790.7 days * DLQI score reduction | Standard Error 62.67 |
Comparison: The AUC was analysed using a robust ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed with WOCF. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: <0.00195% CI: [195.69, 472.26]ANCOVA
Secondary
AUC of HECSI-90 From Baseline up to Week 24
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | AUC of HECSI-90 From Baseline up to Week 24 | 51.1 days with 90% reduction in HECSI score | Standard Error 4.11 |
| Alitretinoin Capsules 30 mg Per Capsule | AUC of HECSI-90 From Baseline up to Week 24 | 43.5 days with 90% reduction in HECSI score | Standard Error 4.22 |
Comparison: The AUC was analysed using a robust ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed as non-response. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: <0.00195% CI: [5.81, 22.86]ANCOVA
Secondary
Change in HECSI Score From Baseline to Week 24
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.
Time frame: 24 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | Change in HECSI Score From Baseline to Week 24 | -69.6 score on a scale | Standard Error 3.78 |
| Alitretinoin Capsules 30 mg Per Capsule | Change in HECSI Score From Baseline to Week 24 | -45.1 score on a scale | Standard Error 3.77 |
Comparison: The change from baseline was analysed using an ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed with WOCF. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: <0.00195% CI: [-32.55, -16.36]ANCOVA
Secondary
Change in HESD Itch Score (Weekly Average) From Baseline to Week 12
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | Change in HESD Itch Score (Weekly Average) From Baseline to Week 12 | -3.0 score on a scale | Standard Error 0.22 |
| Alitretinoin Capsules 30 mg Per Capsule | Change in HESD Itch Score (Weekly Average) From Baseline to Week 12 | -2.4 score on a scale | Standard Error 0.21 |
Comparison: The change from baseline was analysed using an ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed with WOCF. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: =0.00595% CI: [-1.12, -0.2]ANCOVA
Secondary
Change in HESD Pain Score (Weekly Average) From Baseline to Week 12.
The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.
Time frame: 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Delgocitinib Cream 20 mg/g | Change in HESD Pain Score (Weekly Average) From Baseline to Week 12. | -2.9 score on a scale | Standard Error 0.23 |
| Alitretinoin Capsules 30 mg Per Capsule | Change in HESD Pain Score (Weekly Average) From Baseline to Week 12. | -2.3 score on a scale | Standard Error 0.23 |
Comparison: The change from baseline was analysed using an ANCOVA model with effects of treatment group, hyperkeratotic/non-hyperkeratotic subtype and baseline value of the score. Missing data was imputed with WOCF. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: =0.01895% CI: [-1.08, -0.1]ANCOVA
Secondary
HECSI-90 at Week 12
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Delgocitinib Cream 20 mg/g | HECSI-90 at Week 12 | 96 Participants |
| Alitretinoin Capsules 30 mg Per Capsule | HECSI-90 at Week 12 | 65 Participants |
Comparison: The difference in response rates was analysed using the Cochran-Mantel-Haenszel test stratified by hyperkeratotic/non-hyperkeratotic subtype. Missing data was imputed as non-response. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: =0.00395% CI: [4.34, 20.78]Cochran-Mantel-Haenszel
Secondary
IGA-CHE TS at Week 12.
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.
Time frame: 12 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Delgocitinib Cream 20 mg/g | IGA-CHE TS at Week 12. | 68 Participants |
| Alitretinoin Capsules 30 mg Per Capsule | IGA-CHE TS at Week 12. | 42 Participants |
Comparison: The difference in response rates was analysed using the Cochran-Mantel-Haenszel test stratified by hyperkeratotic/non-hyperkeratotic subtype. Missing data was imputed as non-response. Data after initiation of rescue treatment or permanent discontinuation of IMP was treated as missing.p-value: =0.00495% CI: [3.31, 17.87]Cochran-Mantel-Haenszel
Secondary
Number of AEs Leading to IMP Discontinuation up to Week 24
The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).
Time frame: 24 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Delgocitinib Cream 20 mg/g | Number of AEs Leading to IMP Discontinuation up to Week 24 | 4 events |
| Alitretinoin Capsules 30 mg Per Capsule | Number of AEs Leading to IMP Discontinuation up to Week 24 | 44 events |
Secondary
Number of Treatment-emergent AEs From Baseline up to Week 26
An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Delgocitinib Cream 20 mg/g | Number of Treatment-emergent AEs From Baseline up to Week 26 | 280 events |
| Alitretinoin Capsules 30 mg Per Capsule | Number of Treatment-emergent AEs From Baseline up to Week 26 | 620 events |
Secondary
Number of Treatment-emergent SAEs From Baseline up to Week 26
A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.
Time frame: 26 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Delgocitinib Cream 20 mg/g | Number of Treatment-emergent SAEs From Baseline up to Week 26 | 5 events |
| Alitretinoin Capsules 30 mg Per Capsule | Number of Treatment-emergent SAEs From Baseline up to Week 26 | 12 events |